COMMUNIQUÉS West-GlobeNewswire

Averly Health launches to transform cardiometabolic care in the UK
05/10/2026
Joint venture between Reset Health and Pharmacy2U creates the first and only fully integrated national cardiometabolic care provider. Averly Health will set a new standard for access and outcomes to transform the [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
05/10/2026
COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026
05/10/2026
MELBOURNE, Australia and OXFORD, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today [...]
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
Flyte Aviation Launches Under NYSE American Ticker “VJET”
05/10/2026
Flyte Believes Its Proprietary Technology, Data, and Digital Booking Platform Can Disrupt the $11.6 Billion US Private Jet Charter Market Company believes its newly built AI-technology stack can fundamentally transform [...]
Digbi Health Study of Nearly 16,000 Members Finds Precision Biology GI Care Delivers IBS Relief at Scale
05/10/2026
Combining Gut microbiome, genetic, and glucose signals delivers unprecedented personalized care to bring clinically meaningful relief to more than half of symptomatic members MOUNTAIN VIEW, Calif., Oct. 05, 2026 (GLOBE [...]
Upgrade of revenue and operating profit guidance
05/10/2026
ANNOUNCEMENT NO. 317 5 October 2026 ChemoMetec maintained its positive momentum in the first quarter of the 2026/27 financial year, supported by higher-than-expected demand for our instruments, with the NC-203 being a [...]
Elevate Holistics Launches Telehealth Platform for At-Home, Low-Dose Ketamine Care
05/10/2026
Tulsa, Oklahoma, Oct. 04, 2026 (GLOBE NEWSWIRE) -- Elevate Holistics , a telehealth provider focused on accessible, clinician-guided wellness care, announces the launch of its online ketamine telehealth platform, [...]
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
04/10/2026
SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8: [...]
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
05/10/2026
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease MILAN, Oct. 04, 2026 (GLOBE [...]
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
03/10/2026
Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in [...]
VB Health Launches Public Seven-Part Supplement Quality Standard
03/10/2026
New company-wide standard, effective across the VB Health portfolio, establishes requirements for research, clinically relevant dosing, formula transparency, sourcing, U.S. manufacturing and every-batch testing DENVER, [...]
LAST CALL - Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 ($55,000 CAD based on current exchange rate) research grant to advance microbiota research in human health & disease.
02/10/2026
MONTREAL, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to supporting scientific projects that explore the microbiome, is inviting grant [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced [...]
Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System
02/10/2026
Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissions HOLLISTER, Calif., Oct. 02, 2026 ( [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of [...]

Pages